Authorization

Helius Medical Technologies, Inc. Announces Results of Matters Submitted for Vote at 2019 Annual Meeting of Stockholders

NEWTOWN, Pa., July 12, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (a??Heliusa?? or the a??Companya??), a neurotech company focused on neurological wellness, announced today the results of the matters submitted for voting at the annual meeting of stockholders (a??Annual Meetinga??).
The Annual Meeting was held on June 12, 2019. The stockholders considered two proposals, each of which is described in more detail in the Companya??s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2019.A A Of the 25,866,211 shares of Class A Common Stock outstanding as of the record date, 15,476,277 shares, or 59.83%, were present or represented by proxy at the Annual Meeting.A A Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.A Proposal No. 1:A A Election of seven directors of the Company to serve until the 2020 annual meeting of stockholders of the Company and until their respective successors are elected and qualified. The votes were cast as follows:

Name







VotesA For







VotesA Withheld



Philippe Deschamps







11,143,698







63,752



Dane C. Andreeff







10,930,030







277,420



Thomas E. Griffin











11,175,633







31,817







Huaizheng Peng







11,073,143







134,307







Edward M. Straw











11,149,306







58,144







Mitchell E. Tyler







11,176,198







31,252







Blane Walter











10,609,048







603,402





Broker Non-Votes: 4,268,827A  All nominees were elected.Proposal No. 2:A A Ratification of the selection of BDO USA, LLP as the Companya??s independent registered public accounting firm for the fiscal year ending December 31, 2019. The votes were cast as follows:









VotesA For







VotesA Against







Abstained







Ratification of Selection of BDO USA, LLP







15,429,313







14







46,950





The selection of BDO USA, LLP was ratified.About Helius Medical Technologies, Inc.Helius Medical Technologies is a neurotech company focused on neurological wellness.A  The Companya??s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the braina??s ability to heal itself.A  The Companya??s first commercial product is the Portable Neuromodulation Stimulator (PoNSa??).A  For more information, visit www.heliusmedical.com.About the PoNS Device and PoNS TreatmentThe Portable Neuromodulation Stimulator (PoNS) is a licensed class II, noninvasive, medical device in Canada intended for use as an acute treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The device is limited to prescription use. The PoNS is an investigational medical device in the United States, the European Union (a??EUa??), and Australia (a??AUSa??), and it is currently under review for clearance by an EU Notified Body and the AUS Therapeutic Goods Administration. PoNS Treatmenta?? is currently not commercially available in the United States, the European Union or Australia.Investor Relations Contact:Westwicke Partners on behalf of Helius Medical Technologies, Inc.Mike Piccinino, CFAinvestorrelations@heliusmedical.com
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2019    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728
293031